This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. 1.Neuroendocrine measures of opioid activity in alcohol-dependent subjects will be diminished immediately following acute alcohol withdrawal (day 5) relative to age-matched controls and will increase during early abstinence (day 30) approaching control levels. 2.PET-derived mu and delta opioid receptor density will be elevated imediately following acute alcohol withdrawal (day 5) relative to age-matched controls and will decrease during early abstience (day 30) approaching control levels. This receptor density elevation reflects a compensatory increase i response to low opioid activity. 3.Alcohol craving will positively correlate with mu-and delta-receptor density and the ASN/ASP mu opioid receptor polymorphism. Craving will negatively correlate with neuroendocrine measures of opioid activity. 4. The ASN/ASP mu opioid receptor polymorphism will be associated with naltrexone treatment effectiveness, and will predict those patients who are most likely to relapse during or immediately following naltrexone treatment. 5. High alcohol craving, elevated mu and delta receptor density, the ASN/ASP mu opioid receptor polymorphism and high opioid sensitivity will be negatively associated with naltresone treatment effectiveness, and will predict those patients who are most likely to relapse during or immediately following naltrexone treatment. This protocol represents the integration of three NIH-funded RO1 applications (Frost, RO1-AA11872; Wand, RO1-AA12303, McCaul, RO1-AA11855). We will study a common pool of subjects who will participate in a comprehensive characterization of opioid system and opioid medication efficacy. This protocol will accomplish five specific aims: 1. To examine neuroendocrine measures of endogenous opioid activity immediately following alcohol withdrawal (5 day), through early abstinence (30 day) and following naltrexone dose induction. 2. To examine PET-derived measure of mu- and delta-opioid receptor density immediately following alcohol withdrawal (5 day), through early abstinence ( 30day) and following naltrexone dose induction. 3. To examine subjective measures of craving, mood and alcohol withdrawal severity during alcohol withdrawal (5 day), through early abstience (30 day) and following naltrexone dose induction. 4. To examine the realtionship of the ASN/ASP mu opioid receptor polymorphism to neuroendocrine, PET and subjective measures associated with the opioid system. 5. To esamine the utility of mu-and delta-opioid receptor polymorphism and subjective measures associated with alchold withdrawal and craving as predictors of medication effectiveness during outpatient naltrexone treatment.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000052-45
Application #
7378782
Study Section
Special Emphasis Panel (ZRR1-CR-1 (01))
Project Start
2005-12-01
Project End
2006-11-30
Budget Start
2005-12-01
Budget End
2006-11-30
Support Year
45
Fiscal Year
2006
Total Cost
$24,523
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Aboud, Katherine S; Barquero, Laura A; Cutting, Laurie E (2018) Prefrontal mediation of the reading network predicts intervention response in dyslexia. Cortex 101:96-106
Kattan, Meyer; Bacharier, Leonard B; O'Connor, George T et al. (2018) Spirometry and Impulse Oscillometry in Preschool Children: Acceptability and Relationship to Maternal Smoking in Pregnancy. J Allergy Clin Immunol Pract 6:1596-1603.e6
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Salemi, Parissa; Skalamera Olson, Julie M; Dickson, Lauren E et al. (2018) Ossifications in Albright Hereditary Osteodystrophy: Role of Genotype, Inheritance, Sex, Age, Hormonal Status, and BMI. J Clin Endocrinol Metab 103:158-168
Robert BraĊĦi?, James; Mari, Zoltan; Lerner, Alicja et al. (2018) Remission of Gilles de la Tourette Syndrome after Heat-Induced Dehydration. Int J Phys Med Rehabil 6:
Altman, Matthew C; Whalen, Elizabeth; Togias, Alkis et al. (2018) Allergen-induced activation of natural killer cells represents an early-life immune response in the development of allergic asthma. J Allergy Clin Immunol 142:1856-1866
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786
Juraschek, Stephen P; Miller 3rd, Edgar R; Appel, Lawrence J (2018) Orthostatic Hypotension and Symptoms in the AASK Trial. Am J Hypertens 31:665-671
Elion, Richard A; Althoff, Keri N; Zhang, Jinbing et al. (2018) Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 78:62-72
Al-Sofiani, Mohammed E; Yanek, Lisa R; Faraday, Nauder et al. (2018) Diabetes and Platelet Response to Low-Dose Aspirin. J Clin Endocrinol Metab 103:4599-4608

Showing the most recent 10 out of 1014 publications